Company also announces FDA approval of TAXUS(R) Express2(TM) Stent System
for treatment of in-stent restenosis
NATICK, Mass., Sept. 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Express2(TM) Atom(TM) Paclitaxel-Eluting Coronary Stent System. The TAXUS Express Atom Stent is a highly deliverable drug-eluting stent (DES) specifically designed for treating small coronary vessels. It is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter. No other DES for sale in the U.S. market is approved for use in vessels smaller than 2.50 mm in diameter. The Company plans to launch the product immediately.
The Company today also announced FDA approval of its TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System for the treatment of in-stent restenosis in bare-metal stents. This is the first such approval granted by the FDA, making the TAXUS Express2 Stent System the only drug-eluting stent approved in the United States for the treatment of in-stent restenosis in bare-metal stents.
"The TAXUS Express Atom Stent will provide better options for U.S.
patients with coronary artery disease in small vessels," said Gregg Stone,
M.D., Chairman of the Cardiovascular Research Foundation and Professor of
Medicine at Columbia University Medical Center, and Principal Investigator
of the TAXUS IV and V clinical trials. "This is a welcome addition to the
range of available drug-eluting stents, since patients with small vessels
who are currently treated with bare-metal stents experience high rates of
restenosis. In the TAXUS V clinical trial, the TAXUS
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved